Global Point of Care Diagnostics Market Size

Point of care (POC) Diagnostics Market Analysis

The point-of-care (POC) diagnostics market size is currently valued at USD 38.03 billion and is expected to register a CAGR of 9.8% during the forecast period.

The COVID-19 pandemic had a significant impact on the growth of the POC diagnostics market. For instance, an article published by the journal Cureus in August 2022 reported that with the emergence of COVID-19, testing became essential for containment and mitigation purposes, and this led to the development of rapid COVID-19 testing. Thus, the COVID-19 pandemic surged the demand for POC diagnostics. However, in the current scenario, due to the ease, affordability, reduced incidence of complications, and faster turn-around times of POC diagnostics, the demand for POC diagnostics is expected to witness significant growth over the forecast period.

The factors that are driving the growth of the studied market are the rising prevalence of chronic and infectious diseases, the increasing number of regulatory approvals for novel immunoassay techniques and technological advancements, and the rising usage of home-based POC devices.

The prevalence of chronic and infectious diseases, such as diabetes, rheumatism, and malaria, is increasing globally, which is propelling the demand for POC diagnostics. For instance, in December 2022, World Health Organization (WHO) reported that malaria is a life-threatening disease, and in the year 2021, there were an estimated 247 million cases of malaria worldwide. Similarly, an article published by NCBI in May 2021, reported that the global prevalence of rheumatoid arthritis (RA) was 460 per 100,000 population during 2020-2021. Thus, a high number of chronic and infectious diseases recorded globally is increasing the demand for rapid diagnostics, thereby increasing the demand for POC diagnostics and thus driving the growth of the studied market.

Moreover, the increasing number of regulatory approvals for novel immunoassay techniques, technological advancements, and the rising usage of home-based POC devices is expected to complement the growth of the studied market over the forecast period. For instance, in July 2022, BioGX launched CE-marked, three-gene multiplex POC COVID-19 test. These tests make use of BioGX's incredibly effective Xfree direct sample testing chemistry, which is present in their Xfree COVID-19 Direct RT-PCR assay, which has been cleared for emergency use by the United States Food and Drug Administration (USFDA). Thus, regulatory approvals for new product launches are contributing to the growth of the studied market.

Furthermore, an article published by Mylab Discovery Solutions in March 2022 reported that POC diagnostics, which are often characterized by being independent of laboratory infrastructure and being highly affordable, can greatly improve the accessibility of diagnostics. The article also quoted that for the people living in low and middle income countries where the healthcare distribution is quite uneven, the use of POC tests is growing as an important tool to increase diagnostic coverage of the population, and thus demand for POC is constantly increasing, thereby driving the growth of the studied market.

Thus, due to the rising prevalence of chronic and infectious diseases, the increasing number of regulatory approvals for novel immunoassay techniques and technological advancements, and the rising usage of home-based POC devices. However, factors such as product recall incidence by the major players in the market, stringent regulatory policies by the governments, and reimbursement issues will impede the growth of the POC diagnostics market during the forecast period.